en · de · es
aod-9604-notes.peptides1004.com › Wiki › Measurement And Storage Practices — Questions and Answers

Measurement And Storage Practices — Questions and Answers

By Editorial Desk · published 2025-09-20 · last reviewed 2025-10-28 · Wiki

If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-10-28. Where a claim depends on a specific study, the study is described rather than over-claimed.

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form
SolubilitySoluble in waterAlso soluble in aqueous buffers
Storage temperature-20°C or belowProtect from light and moisture
Analytical methodRP-HPLCPurity and identity assessment
Mass confirmationMass spectrometryVerifies molecular mass

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Related pages on this site

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Reference notes

2 GSH + ROOH → GSSG + ROH + H2O Other enzymes, such as glutaredoxins, generate glutathione disulfide through thiol-disulfide exchange with protein disulfide bonds or other low molecular mass compounds, such as coenzyme A disulfide or dehydroascorbic acid.

=== Pyrrolidines and Pyrrolidinophenones === Pyrrolidines are amphetamines with a pyrrolidine group. Pyrrolidinophenones (also called Pyrovalerones) are cathinones (βk-amphetamines) with a pyrrolidine group.

=== Patentability issues === As indicated above, some mammals typically used for food production (such as goats, sheep, pigs, and cows) have been modified to produce non-food products, a practice sometimes called pharming. Use of genetically modified goats has been approved by the FDA and EMA to produce ATryn, i.e. recombinant antithrombin, an anticoagulant protein drug. These products "produced by turning animals into drug-manufacturing 'machines' by genetically modifying them" are sometimes termed biopharmaceuticals. The patentability of such biopharmaceuticals and their process of manufacture is uncertain. Probably, the biopharmaceuticals themselves so made are unpatentable, assuming that they are chemically identical to the preexisting drugs that they imitate. Several 19th-century United States Supreme Court decisions hold that a previously known natural product manufactured by artificial means cannot be patented. An argument can be made for the patentability of the process for manufacturing a biopharmaceutical, however, because genetically modifying animals so that they will produce the drug is dissimilar to previous methods of manufacture; moreover, one Supreme Court decision seems to hold open that possibility. On the other hand, it has been suggested that the recent Supreme Court decision in Mayo v.

Sources: en.wikipedia.org

Reference notes

At 200–300 °C, if oxygen has not been excluded, the carbonaceous residue may start to burn, in a highly exothermic reaction, often with no or little visible flame. Once carbon combustion starts, the temperature rises spontaneously, turning the residue into a glowing ember and releasing carbon dioxide and/or monoxide. At this stage, some of the nitrogen still remaining in the residue may be oxidized into nitrogen oxides like NO2 and N2O3. Sulfur and other elements like chlorine and arsenic may be oxidized and volatilized at this stage. Once combustion of the carbonaceous residue is complete, a powdery or solid mineral residue (ash) is often left behind, consisting of inorganic oxidized materials of high melting point. Some of the ash may have left during combustion, entrained by the gases as fly ash or particulate emissions. Metals present in the original matter usually remain in the ash as oxides or carbonates, such as potash. Phosphorus, from materials such as bone, phospholipids, and nucleic acids, usually remains as phosphates.

As of 2023, Thermos and THERMOS remain a registered trademark in some countries, including the United States, but the lowercase "thermos" was declared a genericized trademark by court action in the United States in 1963.

Since Operation Inherent Resolve began, U.S. airstrikes have been supported by Green Beret adviser teams, helping stop the advances of ISIL. Green Berets from the 5th SFG deployed to Jordan in support of OIR. On November 4, 2016, a small convoy carrying Green Berets was returning to the base after a training exercise when a Jordanian guard, after waving the first vehicle through the entry control point at the base, then opened fire on the second vehicle killing 2 Green Berets, U.S. troops from the vehicle behind opened fire, another Green Beret was killed but a fourth, who was wounded, shot the Jordanian, severely wounding him.

Sources: en.wikipedia.org

Frequently asked questions

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

What are the recommended storage conditions for AOD-9604?

Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.

What quality issues can arise with AOD-9604 products?

Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network